Analysed SYNDAX PHARMACEUTICALS INC (SNDX:NASDAQ) News Sources
Syndax Pharmaceuticals Inc (SNDX) Q1 2026 Earnings Call Highlights: Record Revenue Growth and ...
01-05-2026
yahoo.com
Syndax (SNDX) Narrows Losses as Revuforj and Niktimvo Gain Traction - What’s Really Shifting?
01-05-2026
yahoo.com
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
06-05-2026
yahoo.com
Syndax Highlights 12 Revuforj® (revumenib) Abstracts Accepted for EHA 2026, Advancing Leadership in Menin Inhibition
12-05-2026
yahoo.com
Why Syndax Pharmaceuticals (SNDX) is One of the Best Small Cap Stocks to Buy for 10x Potential
14-05-2026
yahoo.com
Syndax Announces Four Revuforj® (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data
21-05-2026
yahoo.com
Assessing Whether Syndax Pharmaceuticals (SNDX) Looks Undervalued After Recent Share Price Weakness
24-05-2026
yahoo.com
Syndax to Host R&D Day Highlighting its Late-Stage Programs and Early-Stage Assets on July 14, 2026
01-06-2026
yahoo.com
What is the current price of SYNDAX PHARMACEUTICALS INC (SNDX:NASDAQ)?
The current price of SYNDAX PHARMACEUTICALS INC (SNDX:NASDAQ) is $18.39.
SYNDAX PHARMACEUTICALS INC (SNDX:NASDAQ) absolute price change since previous trading day?
The absolute price change of SYNDAX PHARMACEUTICALS INC (SNDX:NASDAQ) since the previous trading day is $-0.46.
SYNDAX PHARMACEUTICALS INC (SNDX:NASDAQ) percentage price change since previous trading day?
The percentage price change of SYNDAX PHARMACEUTICALS INC (SNDX:NASDAQ) since the previous trading day is -2.4403%.
What is the most recent average sentiment score for SYNDAX PHARMACEUTICALS INC (SNDX:NASDAQ)?
The most recent average sentiment score for SYNDAX PHARMACEUTICALS INC (SNDX:NASDAQ) is 82 out of 100.
What is the most recent average sentiment for SYNDAX PHARMACEUTICALS INC (SNDX:NASDAQ)?
The most recent sentiment for SYNDAX PHARMACEUTICALS INC (SNDX:NASDAQ) is .
SEC-8K** Filing Available For SYNDAX PHARMACEUTICALS INC (SNDX:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.